Similarly, our study revealed that IDH1 activates the tumor immune microenvironment by inhibiting tumor cell glycolysis, and similarly, Scu exerts similar effects in vivo by recruiting tumor-infiltrating immune cells and blocking the expression of the immunosuppressive factor PD-L1, resulting in antitumor immunity. This evidence concerns the gene IDH1 and neoplasm.